Inventor · disambiguated record
Philipp Beckhove
Also filed as: BECKHOVE PHILIPP
6 granted patents·10 pending applications·2 citations·filing 2004–2025
68Inventor score
Files withIOMX THERAPEUTICS AG5DEUTSCHES KREBSFORSCH4DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES OEFFENTLICHEN RECHTS4BAYER AG2SCHIRRMACHER VOLKER1
Top patents by PatentIndex Score
16 records- 0170US8142791B2Multi-modal cancer therapy using viral hitch-hikingSCHIRRMACHER VOLKER·Filed 2007·Granted Mar 27, 2012·2 cites·2 claims
- 0264US11802285B2Cytotoxic T cell response modifiersDEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES OEFFENTLICHEN RECHTS·Filed 2019·Granted Oct 31, 2023·0 cites·10 claims
- 0364US2025340886A1Intracellular kinase associated with resistance against anti-tumour immune responses, and uses thereofIOMX THERAPEUTICS AG·Filed 2025·Application pending·0 cites
- 0455US9994854B2Cytotoxic T cell response modifiersDEUTSCHES KREBSFORSCH·Filed 2014·Granted Jun 12, 2018·0 cites·43 claims
- 0550US12221479B2Pharmaceutical combination of anti CEACAM6 and TIM3 antibodiesBAYER AG·Filed 2019·Granted Feb 11, 2025·0 cites·11 claims
- 0649US2018298388A1Cytotoxic t cell response modifiersDEUTSCHES KREBSFORSCH·Filed 2018·Application pending·0 cites
- 0748US12338440B2Intracellular kinase associated with resistance against anti-tumour immune responses, and uses thereofIOMX THERAPEUTICS AG·Filed 2018·Granted Jun 24, 2025·0 cites·33 claims
- 0848US2011171290A1Inhibition of angiogenesis and tumor metastasisDEUTSCHES KREBSFORSCH·Filed 2009·Application pending·0 cites
- 0945US2022010017A1Pharmaceutical combination of anti-ceacam6 and either anti-pd-1 or anti-pd-l1 antibodies for the treatment of cancerBAYER AG·Filed 2019·Application pending·0 cites
- 1041US2023228760A1Intracellular kinase associated with resistance against t-cell mediated cytotoxicity, and uses thereofIOMX THERAPEUTICS AG·Filed 2021·Application pending·0 cites
- 1140US7842782B2Heparanase-derived peptides for vaccination of tumor patientsDEUTSCHES KREBSFORSCH·Filed 2004·Granted Nov 30, 2010·0 cites·3 claims
- 1237US2019263906A1Immune modulators for reducing immune-resistance in melanoma and other proliferative diseasesDEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES OEFFENTLICHEN RECHTS·Filed 2017·Application pending·0 cites
- 1336US2020164068A1Modulators of tumor immune resistance for the treatment of cancerDEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES OEFFENTLICHEN RECHTS·Filed 2017·Application pending·0 cites
- 1435US2020024347A1Or10h1 antigen binding proteins and uses thereofIOMX THERAPEUTICS AG·Filed 2017·Application pending·0 cites
- 1533US2019054110A1Modulators of ccr9 for treating tumor resistance to immune responsesDEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES OEFFENTLICHEN RECHTS·Filed 2017·Application pending·0 cites
- 1632US2021061908A1Antibodies targeting, and other modulators of, an immunoglobulin gene associated with resistance against anti-tumour immune responses, and uses thereofIOMX THERAPEUTICS AG·Filed 2019·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Philipp Beckhove files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →